Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, expects GlaxoSmithKline's combination inhaler, Advair/Seretide, to capture a significant share of the asthma market because it is convenient and simplifies treatment regimens. Driven by such combination therapies and the introduction of the biologic therapy omalizumab, total sales for asthma drugs in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will reach $11.4 billion in 2011.
"Clinical studies have shown that the use of long-acting beta2 agonists in combination with low to medium doses of inhaled corticosteroids is more effective and safer than the use of high doses of inhaled corticosteroids as a monotherapy," said Carole Gleeson, analyst at Decision Resources.
The new Pharmacor study entitled Asthma also finds that significant market opportunity exists for safe and effective therapies for severe, refractory asthma.
"Omalizumab can help patients with severe, refractory asthma by reducing, or even eliminating, their need for oral corticosteroids and by preventing exacerbations," continued Ms. Gleeson. "However, a significant drawback to omalizumab is the requirement for subcutaneous injections, a factor that might limit its acceptance by both patients and physicians. Although this monoclonal antibody appears to be relatively free of side effects in clinical trials, long-term side effects have yet to be determined."
Thirty-one million people in the world's seven major pharmaceutical markets were diagnosed with asthma in 2001, the most widespread serious chronic disease of childhood. As a chronic inflammatory disorder, asthma causes significant morbidity in affected individuals, including permanent structural damage to the airways and long-term decreases in lung function.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Asthma is an Immune and Inflammatory Disorders study.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.dresources.com/